Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
Frontiers in Oncology · 15.06.2026 · 16
DOI: 10.3389/fonc.2026.1849030 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 15.06.2026. Verfasst von Wen Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Yantaishan Hospital, Yantai, Shandong, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Recurrent or metastatic nasopharyngeal carcinoma (RM−NPC) is associated with poor prognosis. PD−1 inhibitors combined with chemotherapy have become the standard first−line treatment, but the comparative efficacy, long−term survival, and safety of different PD−1 inhibitors remain unclear. This study aimed to evaluate the impact of distinct PD−1 inhibitors plus chemotherapy for RM−NPC.
Methods
We conducted a systematic review and single−arm meta−analysis including 19 studies with 1459 patients. Outcomes included objective response rate (ORR), disease control rate (DCR), progression−free survival (PFS), overall survival (OS), and grade ≥3 treatment−related adverse events (TRAEs). Pooled analyses and subgroup comparisons stratified by PD−1 inhibitor type were performed.
Results
The pooled ORR was 64% and DCR was 94% across all regimens. Subgroup analyses stratified by PD−1 inhibitor type revealed significant differences: toripalimab−based regimens achieved the highest ORR and longest median PFS of 21.4 months, while tislelizumab plus chemotherapy yielded the most favorable median OS of 45.3 months. Camrelizumab plus chemotherapy showed a median OS of 34.5 months. Subgroup analysis by study design (randomized controlled trials vs. non−randomized single−arm studies) confirmed highly consistent outcomes, supporting the robustness of pooled estimates. The pooled incidence of grade ≥3 TRAEs was 13%, with comparable safety profiles across all PD−1 inhibitors and no unexpected safety signals.
Conclusions
PD−1 inhibitors combined with chemotherapy provide robust efficacy and durable long−term survival benefits in RM−NPC. Toripalimab, tislelizumab, and camrelizumab demonstrate superior therapeutic effects compared with other agents, with toripalimab showing optimal tumor response and PFS, and tislelizumab offering the best long−term OS. The findings support individualized PD−1 inhibitor selection in clinical practice and confirm the reliability of single−arm meta−analyses combining randomized and non−randomized evidence for agent−stratified comparison. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420261361323.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Yantaishan Hospital, Yantai, Shandong, China.
- Department of Otolaryngology, Ganzhou People's Hospital, Ganzhou, Jiang Xi, China.
Zitieren
APA
Sun, W., Liu, Y., Dong, H., & Huang, Y. (2026). Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1849030
Vancouver
Sun W, Liu Y, Dong H, Huang Y. Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1849030
BibTeX
@article{Sun2026,
author = {Sun, Wen and Liu, Yansha and Dong, Hui and Huang, Yun},
title = {Efficacy, long-term survival and safety of different PD-1 inhibitors plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1849030}
}
EUVIMED